Showing results (41-50 of 74) with videos related to
Sort By:
Pageof 8
Journal of the American Academy of Dermatology|June 6, 2021
Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled studyBrett King, Justin Ko, Seth Forman, et al.JAMA Dermatology|August 14, 2024
Baricitinib Withdrawal and Retreatment in Patients With Severe Alopecia Areata: The BRAVE-AA1 Randomized Clinical TrialBrett King, Justin Ko, Ohsang Kwon, et al.Frontiers in Immunology|November 29, 2023
Inhibition of T-cell activity in alopecia areata: recent developments and new directionsThierry Passeron, Brett King, Julien Seneschal, et al.American Journal of Clinical Dermatology|April 11, 2025
Safety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials Over a Median of 2.3 Years and Up to 4 Years of TreatmentBrett King, Arash Mostaghimi, Yutaka Shimomura, et al.Journal of the American Academy of Dermatology|April 1, 2022
Phase 2 randomized, dose-ranging trial of CTP-543, a selective Janus Kinase inhibitor, in moderate-to-severe alopecia areataBrett King, Natasha Mesinkovska, Paradi Mirmirani, et al.American Journal of Clinical Dermatology|March 31, 2026
Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical StudiesMaryanne Senna, Jennifer Soung, Ignasi Figueras, et al.The British Journal of Dermatology|September 14, 2023
When to expect scalp hair regrowth during treatment of severe alopecia areata with baricitinib: insights from trajectories analyses of patients enrolled in two phase III trialsBrett King, Jerry Shapiro, Manabu Ohyama, et al.The British Journal of Dermatology|October 21, 2024
Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areataMelissa Piliang, Jennifer Soung, Brett King, et al.The Journal of Clinical Investigation|November 3, 2025
Cellular profiling identifies targetable T cell phenotypes in lymphocytic variant hypereosinophilic syndromeKristy Tefft, Amy Wang, Zachary Z Reinstein, et al.Dermatology and Therapy|October 14, 2025
Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia AreataBrett King, Amy McMichael, Rodney Sinclair, et al.Pageof 8